摘要
Abstract
Objective To investigate the curative efficacy and pharmacoeconomics of the medication with febuxostat in the treatment of gouty arthritis patients. Methods A total of 206 patients with gouty arthritis who were diagnosed at Nanjing First Hospital from October 2015 to September 2016 were selected as the study objects. According to 2015 Chinese guidelines for diagnosis and treatment of rheumatism, these patients were treated for 1 year, a total of 68 patients with good compliance, close follow-up, regular medication were devided into group A, and other 59 patients with poor compliance, no close follow-up, and a total of less than 3 months of uric acid-lowering drugs in one year were divided into group B. The total amount of the remaining 79 patients was uncertain and was not included in the study. By comparing the efficacy of treatment in the two groups of patients for one year, and calculating the medical expenditure for one year, the economic indicators were analyzed. Results After a year of treatment, the average uric acid in group A decreased from (545.85±34.23)mmol/L to (312.34±34.48) mmol/L (P<0.0001), and the average uric acid (548.68±32.58) mmol/L in group B decreased to (542.75±35.56) mmol/L (P>0.05), and the serum uric acid level in group A was significantly lower than in group B (P<0.0001). The average amount of gout in group A decreased from (6.60±1.83) cm3 to (2.99±1.21) cm3 (P<0.0001), and was decreased from (6.45±1.59) cm3 to (6.73±1.39) cm3 in group B (P>0.05). The volume of gout in group A was deceased more than that of group B (P<0.0001). The number of gout attacks in group A was significantly decreased, and the number of gout attacks in group B was not significantly decreased. A total of 68 patients in group A were hospitalized for 12 times, with an average of 0.18 times per person. In group B, there were 47 patients in the hospital, with an average of 0.79 per person. The total cost of Group A is 8414.71 yuan/(person·year), the total cost of Group B is 8162.23 yuan/(person·year); the C/E value of Group A is 152.6, and the C/E value of Group B is 1156.1, so the treatment effect of group A was better than group B. Conclusion The therapeutic efficacy and economic effects of patients who regularly take febuxostat for gouty arthritis are better than those who with irregular medication.关键词
痛风性关节炎/非布司他/治疗疗效/经济学评价Key words
Gouty arthritis/Febuxostat/Therapeutic efficacy/Economic evaluation分类
医药卫生
